拓扑替康联合卡铂治疗复发性小细胞肺癌临床观察  

Topotecan in combination with carboplatin in the treatment of recurrent small cell lung cancer

作　　者：程宝智[1] 谢斌[1] 王萍[1] 胡传朋[1] 

机构地区：[1]安徽省六安市人民医院肿瘤内科,安徽六安237005

出　　处：《现代肿瘤医学》2010年第4期718-720,共3页Journal of Modern Oncology

摘　　要：目的:观察盐酸拓扑替康联合卡铂治疗复发性小细胞肺癌的疗效及不良反应。方法:对29例复发的小细胞肺癌患者采用CT方案化疗:拓普替康1.2mg/m2,d1-5;卡铂300mg/m2,d5,21天为1周期,至少治疗2周期。结果:CR 1例,PR 11例,SD 12例,PD 5例,总有效率为41.38%,其中敏感型和难治型复发患者的有效率分别为47.62%和25%。结论:拓普替康与卡铂作为二线方案治疗复发性小细胞肺癌,疗效确切。主要不良反应为血液学毒性,及时应用集落刺激因子,可耐受治疗。Objective：To observe the effect and side effects of topotecan in combination with carboplatin in the treatment of recurrent small cell lung cancer.Methods：Twenty-nine patients of recurrent small cell lung cancer enrolled in the study.Topotecan was given at the dose of 1.2mg/m^2 on d1-5 and carboplatin was administered at the dose of 300mg/m^2 on d5 in a cycle of 21 days.The patients were evaluated at least after 2 cycles.Results：One patient got complete response and eleven patients got partial response.The overall response rate was 41.38%,and the response rates of sensitive group and refractory groups were 47.62% and 25% respectively.Conclusion：The regimen of topotecan and carboplatin shows better activity in retreated small cell lung cancer patients.The main toxicity is hematological toxicity and can be tolerated.

关 键 词：拓普替康 卡铂 小细胞肺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]